LPA2 antagonist 1CAS# 1017606-66-4 |
- Atorvastatin Calcium
Catalog No.:BCC2319
CAS No.:134523-03-8
- Pitavastatin Calcium
Catalog No.:BCC3842
CAS No.:147526-32-7
- Pravastatin sodium
Catalog No.:BCC2321
CAS No.:81131-70-6
- Fluvastatin
Catalog No.:BCC1579
CAS No.:93957-54-1
- Fluvastatin Sodium
Catalog No.:BCC2317
CAS No.:93957-55-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1017606-66-4 | SDF | Download SDF |
PubChem ID | 24882686 | Appearance | Powder |
Formula | C20H23Cl2N5O2S2 | M.Wt | 500.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (199.82 mM) DMF : ≥ 100 mg/mL (199.82 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[(2S)-1-[4-(3,4-dichlorophenyl)sulfonylpiperazin-1-yl]propan-2-yl]-7-methylthieno[3,2-d]pyrimidin-4-amine | ||
SMILES | CC1=CSC2=C1N=CN=C2NC(C)CN3CCN(CC3)S(=O)(=O)C4=CC(=C(C=C4)Cl)Cl | ||
Standard InChIKey | BPRNMVDTWIHULJ-AWEZNQCLSA-N | ||
Standard InChI | InChI=1S/C20H23Cl2N5O2S2/c1-13-11-30-19-18(13)23-12-24-20(19)25-14(2)10-26-5-7-27(8-6-26)31(28,29)15-3-4-16(21)17(22)9-15/h3-4,9,11-12,14H,5-8,10H2,1-2H3,(H,23,24,25)/t14-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
LPA2 antagonist 1 Dilution Calculator
LPA2 antagonist 1 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9982 mL | 9.9908 mL | 19.9816 mL | 39.9632 mL | 49.954 mL |
5 mM | 0.3996 mL | 1.9982 mL | 3.9963 mL | 7.9926 mL | 9.9908 mL |
10 mM | 0.1998 mL | 0.9991 mL | 1.9982 mL | 3.9963 mL | 4.9954 mL |
50 mM | 0.04 mL | 0.1998 mL | 0.3996 mL | 0.7993 mL | 0.9991 mL |
100 mM | 0.02 mL | 0.0999 mL | 0.1998 mL | 0.3996 mL | 0.4995 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
LPA2 antagonist 1 is a LPA2 antagonist with an IC50 of 17 nM.
In Vitro:LPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused by LPA in a doses dependent manner[1].
References:
[1]. Beck HP, et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
- Ladanein
Catalog No.:BCN6670
CAS No.:10176-71-3
- Nevadensin
Catalog No.:BCN6806
CAS No.:10176-66-6
- Jaceidin
Catalog No.:BCN5832
CAS No.:10173-01-0
- Sanggenofuran B
Catalog No.:BCN7194
CAS No.:1017277-40-5
- 6alpha,16,18-Trihydroxycleroda-3,13-dien-15,16-olide
Catalog No.:BCN1640
CAS No.:1017233-48-5
- (S)-(+)-4-Benzyl-3-propionyl-2-oxazolidinone
Catalog No.:BCC8399
CAS No.:101711-78-8
- Myzodendrone
Catalog No.:BCN7257
CAS No.:101705-37-7
- 6-O-p-Hydroxybenzoylaucubin
Catalog No.:BCN5831
CAS No.:1016987-87-3
- Sulfocostunolide A
Catalog No.:BCN5830
CAS No.:1016983-51-9
- Olivil monoacetate
Catalog No.:BCN4738
CAS No.:1016974-78-9
- Barpisoflavone A
Catalog No.:BCN4739
CAS No.:101691-27-4
- Cyclo(Phe-Hpro)
Catalog No.:BCN2425
CAS No.:1016899-94-7
- PK 44 phosphate
Catalog No.:BCC2366
CAS No.:1017682-65-3
- Boc-N-Me-Ser-OH
Catalog No.:BCC2613
CAS No.:101772-29-6
- Elliotinol
Catalog No.:BCN5833
CAS No.:10178-31-1
- 7-O-Demethyl-3-isomangostin hydrate
Catalog No.:BCN7882
CAS No.:
- Desacetylmatricarin
Catalog No.:BCN7258
CAS No.:10180-88-8
- TG 100801 Hydrochloride
Catalog No.:BCC1997
CAS No.:1018069-81-2
- Butenafine HCl
Catalog No.:BCC4768
CAS No.:101827-46-7
- Diclazuril
Catalog No.:BCC8937
CAS No.:101831-37-2
- 7-Z-Trifostigmanoside I
Catalog No.:BCN7869
CAS No.:1018898-17-3
- LX-4211
Catalog No.:BCC1714
CAS No.:1018899-04-1
- sodium 4-pentynoate
Catalog No.:BCC1958
CAS No.:101917-30-0
- Dabigatran etexilate benzenesulfonate
Catalog No.:BCC8925
CAS No.:1019206-65-5